Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerRespiratory

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1797270

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1797270

Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC)

PUBLISHED:
PAGES: 283 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market to Reach US$10.1 Billion by 2030

The global market for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) estimated at US$7.5 Billion in the year 2024, is expected to reach US$10.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Osimertinib, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Erlotinib segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 8.3% CAGR

The Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global EGFR - Non-Small Cell Lung Cancer (NSCLC) Market - Key Trends & Drivers Summarized

How Is EGFR Status Influencing Treatment Strategies in NSCLC?

Epidermal Growth Factor Receptor (EGFR) mutations are a key biomarker in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma subtypes. These mutations lead to overactivation of EGFR signaling pathways, promoting uncontrolled cell division and tumor growth. Approximately 10-15% of NSCLC patients in Western populations and up to 40% in Asian populations exhibit EGFR mutations, making molecular testing critical for personalized treatment planning.

Identification of EGFR mutations has enabled the use of targeted therapies, notably tyrosine kinase inhibitors (TKIs), which inhibit aberrant EGFR signaling. These drugs have improved progression-free survival and reduced toxicity compared to conventional chemotherapy. First-generation TKIs such as gefitinib and erlotinib have given way to newer agents like osimertinib, which can overcome resistance mutations such as T790M. As a result, EGFR testing is now a standard component of NSCLC diagnosis in clinical oncology workflows.

What Advancements Are Reshaping Targeted Therapy and Resistance Management?

Recent advancements in EGFR-targeted therapy focus on enhancing drug selectivity, overcoming resistance, and minimizing adverse effects. Third-generation TKIs such as osimertinib have shown efficacy in central nervous system metastases and in patients with acquired resistance to earlier therapies. Research is ongoing into fourth-generation inhibitors designed to target uncommon EGFR mutations or compound mutations that current drugs cannot address effectively.

Liquid biopsy technologies are emerging as non-invasive tools to monitor EGFR mutation status and detect resistance mutations in real time. These tools enable dynamic treatment adjustment and reduce reliance on tissue biopsy. Combination therapies involving TKIs and anti-angiogenic agents, immune checkpoint inhibitors, or chemotherapy are also being studied to prolong response duration and improve survival. These therapeutic innovations are expanding the treatment landscape for EGFR-mutated NSCLC, particularly in relapsed and advanced-stage patients.

Which Patient Populations and Healthcare Systems Are Impacting Market Demand?

The EGFR-NSCLC segment is especially significant in East Asian countries where mutation prevalence is high. In these regions, routine molecular profiling and early-stage treatment with EGFR inhibitors are common clinical practices. In Western healthcare systems, adoption is growing as testing protocols become standardized and supported by reimbursement policies. Aging populations, rising lung cancer incidence, and growing access to genomic testing are contributing to increased identification of eligible patients globally.

Academic medical centers and cancer treatment hospitals play a central role in guiding adoption through research trials, updated treatment guidelines, and educational outreach. Patient awareness of genetic testing and demand for precision oncology is increasing, further promoting EGFR screening at the point of diagnosis. As healthcare systems prioritize value-based care, the shift toward biomarker-driven treatment is becoming more prominent, especially where health outcomes and cost efficiency intersect.

What Is Driving Growth in the EGFR - NSCLC Market?

Growth in the EGFR-NSCLC market is driven by several factors related to biomarker prevalence, drug innovation, and precision oncology uptake. High rates of EGFR mutations in specific populations are supporting broad testing and targeted therapy adoption. Development of next-generation TKIs with improved efficacy against resistant and CNS-involved disease is expanding treatment duration and improving patient outcomes.

Integration of companion diagnostics and reimbursement support for genomic testing are enhancing early identification of targetable mutations. Expansion of clinical trials and regulatory approvals for novel EGFR inhibitors are increasing treatment options, especially in previously under-addressed patient subsets. Rising awareness of personalized medicine and the clinical value of targeted therapies is strengthening physician adoption and system-level integration. These factors are collectively driving sustained investment and therapeutic advancement in the EGFR-NSCLC treatment market.

SCOPE OF STUDY:

The report analyzes the Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Osimertinib, Erlotinib, Afatinib, Gefitinib, Dacomitinib); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen? (Black Diamond Therapeutics)
  • Blueprint Medicines Corp.
  • Boehringer Ingelheim
  • Cullinan Therapeutics
  • Daiichi Sankyo Co., Ltd.
  • Dizal Pharmaceutical
  • Eli Lilly and Company
  • Genentech (Roche Group)
  • Merck & Co., Inc.
  • Mirati Therapeutics
  • Novartis AG
  • Oric Pharmaceuticals
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd.)
  • Takeda Pharmaceutical Company Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Zai Lab

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38790

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of NSCLC Globally Drives Sustained Demand for EGFR-Targeted Therapeutics
    • Increased Adoption of Precision Oncology Approaches Strengthens Business Case for EGFR Mutation Testing and Targeted Therapy
    • Advancements in Liquid Biopsy Technologies Accelerate Non-Invasive Detection of EGFR Mutations
    • Expanding Role of Companion Diagnostics Throws Spotlight on Personalized EGFR Therapy Regimens
    • Regulatory Approvals for Next-Generation EGFR Inhibitors Propel Growth in First-Line and Refractory NSCLC Treatment
    • Growing Use of Osimertinib and Other Third-Generation TKIs Spurs Shift in Standard of Care for EGFR-Positive Patients
    • Emerging Resistance Mutations in EGFR Pathways Generate Opportunities for Combination and Sequential Therapy Approaches
    • Expansion of Molecular Testing Programs in Emerging Markets Enhances EGFR Mutation Identification and Drug Uptake
    • Increasing Enrollment in Clinical Trials for Novel EGFR Agents Sustains Innovation Momentum Across Therapeutic Classes
    • Integration of AI in Biomarker Discovery Enhances Targeted Drug Development for EGFR Subtypes in NSCLC
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Osimertinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Osimertinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Osimertinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Erlotinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Erlotinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Erlotinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Afatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Afatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Afatinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gefitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gefitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Gefitinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dacomitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dacomitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dacomitinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!